12/02/2019 | News release | Distributed by Public on 12/02/2019 16:26
On November 19, 2019, the U.S. Food and Drug Administration approved cenobamate (XCOPRI®) for the treatment of focal epilepsy in adults. This medication will be available in the pharmacy by the spring or summer of 2020. XCOPRI was developed by SK Biopharmaceuticals Co. and their U.S subsidiary SK Life Science Inc.
People with persistent focal seizures can talk to their neurologist about whether a trial with this medicine may be helpful for them.